MOMA Therapeutics has raised $150M across 0 funding rounds, plus 1 undated round. The company is valued at $350M.
MOMA Therapeutics raised $150 million in a Series B round in 2022 to advance its precision oncology programs, backed by investors including Longitude Capital, RA Capital and SoftBank Vision Fund 2. It has also brought in a five-year drug discovery collaboration with Roche.
No date is disclosed for this round.
Each raise joins the axis with its own date and figures.
No filing has been made.
0 dated rounds, newest first.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. MOMA Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
